31 July 2017 EMA/CHMP/BWP/149179/2017 Human Medicines Research and Development Support Division
Agenda - Joint BWP/QWP workshop with stakeholders in relation to prior knowledge and its use in regulatory applications 23 November 2017, European Medicines Agency, London
Purpose Prior knowledge has always been an important tool in designing both manufacturing processes and control strategies for medicinal products. In recent years, it has gained more focus in EU guidelines (e.g. process validation for biotech drug substances; process validation for finished products). Making use of such prior knowledge in regulatory application dossiers, to support manufacturing and control strategies, could be justifiable in certain circumstances. For prior knowledge to be used in this way, good understanding among regulators and industry of the expectations of how it should be documented in regulatory application dossiers is essential. This workshop will address exactly what prior knowledge entails and how it can be used to support product development, manufacturing and control strategies. These general discussions will be further elaborated through a number of specific industry case studies and a discussion of experiences to date of accelerated access schemes. The conclusions from the workshop will be captured in a report, which will be published. Further follow-up guidance may be considered.
Location European Medicines Agency 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Tel. +44 (0)20 3660 6000
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
Agenda Thursday, 23 November 2017, Time: 09:00-17:30 Timings
Topic
8.30-9.00
Arrival and registration
9.00-9.10
Welcome, Introductions & Goals of Workshop
9.10-10.00
1. What is Prior Knowledge? What is (and isn’t) considered to be prior knowledge, how can such prior knowledge be used in regulatory submissions, how to justify its use and how to present it in the dossier.
10.00-11:30
2. Using prior knowledge in product development/design? How to justify applicability of prior knowledge of active substance, excipient or packaging properties from similar products to support formulation design and how to apply prior knowledge from similar products or different product classes to a product in development (e.g. platform technologies, identifying CQAs, informing risk assessments).
11:30-11:45
Coffee
11:45-13:15
3. Using prior knowledge in process development & manufacturing strategy? Using prior knowledge when selecting starting materials and manufacturing processes, supporting design space development, determining validation approaches and criticalities and supporting scale up.
13:15-14:15
Lunch
14:15-15.45
4. How to use prior knowledge in defining the control strategy? How prior knowledge can be used to define an integrated control strategy by using prior knowledge of CQAs when assessing risk to safety and efficacy and clinical experience when setting specifications.
15:45-16:00
Coffee
16.00 -17.00
5. Experiences of accelerated access schemes (PRIME/adaptive/accelerated pathways) Sharing industry and regulator’s perspectives and experience with accelerated access approaches (PRIME/Adaptive pathways), and exploring when and how prior knowledge could be used in this context.
17.00-17.30
6. General discussion, summing up and way forward The lessons learned from the workshop and next steps will be summarized at the end of the meeting.
Agenda - Joint BWP/QWP workshop with stakeholders in relation to prior knowledge and its use in regulatory applications EMA/CHMP/BWP/149179/2017
Jul 31, 2017 - Human Medicines Research and Development Support Division. Agenda ... use of such prior knowledge in regulatory application dossiers, to support manufacturing and control strategies ... of accelerated access schemes.
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs â meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju
Feb 9, 2018 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. â¢. Product
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina SchüÃler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g
Dec 7, 2016 - publication of clinical data (Policy 0070) and revisions to the guidance to industry â Industry Associations Webinar. 9 December 2016, 10:00 to ...
Sep 19, 2017 - 14:00-14:05. 2. Data integrity â early signal detection. - data patterns/trends in data ... 16:20-17:00. 5. Inspections of Ligand Binding Assays (in.
Nov 7, 2017 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union. Telephone ...... Visualisation of choline metabolism in malignant neoplasms ..... A paediatric investigation plan (PIP) is a dev
Jan 23, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be
Oct 24, 2017 - Application of Article 8(2) of the Orphan Regulation ..... propoxy)-phenyl]-methanone, EMA/OD/187/14 Herpes simplex type 1 virus containing.
Jun 14, 2016 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom ... EMA initiatives to support and accelerate early access. 10:00 2.1 ...
6 days ago - EMA/OD/103/14 Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment, EMA/OD/175/14 Allogeneic ...
o Pilot to test draft model ... Endorsement of Enpr-EMA membership criteria Mark Turner/Irmgard. Eichler ... Endorsement of newly received applications.
Jan 23, 2018 - HCP/patient cross-sectional survey and retrospective chart review Post Authorisation. Safety Study to evaluate the effectiveness of the Patient Alert Card for both IV and SC abatacept in a sample of EU countries. Positive Opinion adopt
Jan 8, 2018 - Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. ... EU referral procedures for safety reasons: urgent EU procedures 13. 2.1. ...... clinical data from st
Nov 3, 2016 - Scope: 'Optimising the development of ATMPs to meet patient needs' ... the CAT would like to discuss with company representatives in person.
Jul 7, 2017 - EMEA/V/C/002526. Rapp: G. J. Schefferlie. For adoption: CVMP assessment report on the targeted. PSUR for the period 11.02.14-31.12.16 ...
Oct 23, 2017 - under Article 107i of Directive 2001/83/EC, based on pharmacovigilance data. Action: For adoption of ..... manufacturing process; and 3) removal of the following missing information: special patient groups. Action: For .... analysis of
Jan 8, 2018 - information (RSI) adopted in July 2017. Action: For adoption of advice to CHMP. 7.2.15. Naltrexone hydrochloride, bupropion hydrochloride - MYSIMBA (CAP) -. EMEA/H/C/003687/MEA 004.4. Applicant: Orexigen Therapeutics Ireland Limited. PR